12/28/2012 7:11:06 AM
US-based drug maker Bristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's LaboratoriesBSE 0.00 % (DRL) over the cancer drug Ixempra. Bristol-Myers in its petition filed in the United States District Court of New Jersey alleged that the Indian drug maker has infringed the patents of its drug on three counts. According to the petition, by a letter dated November 13, 2012, DRL notified Bristol-Myers that the Indian drug major had submitted Abbreviated New Drug Application (ANDA) concerning its proposed drug product of Ixabepilone for injection, as required by the FDA rules. DRL's letter further notified that Ixabepilone injection patents are invalid and or will not be infringed by the commercial manufacture, use, offer for sale, or sale of DRL's ANDA product, the petition said.
comments powered by